ReviewBlood cancer journal2018
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
Review in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 102 citations in OpenAlex.
- Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.Blood advances · 2019Trial
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches.Brain and behavior · 2026Review
- Article
- Prognostic parameters and detection of cardiac amyloidosis with hybridEuropean journal of nuclear medicine and molecular imaging · 2026Observational
- AIns (insulin) type amyloidosis in a kidney transplant candidate with a newly identified monoclonal gammopathy.Journal of hematopathology · 2026Article
- Patient with AL amyloidosis with recurrent syncope as the first symptom: case report and literature review.Frontiers in oncology · 2026Article
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.The international journal of cardiovascular imaging · 2025Review
- Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.International journal of hematology · 2023Article
- A Rare Case of Gastrointestinal Amyloidosis Due to Monoclonal Gammopathy of Undetermined Significance.Cureus · 2023Article
- AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects:JACC. CardioOncology · 2022Review
- Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment.BMJ case reports · 2022Article
- The Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- Tandem Mass Spectrometry-Based Amyloid Typing Using Manual Microdissection and Open-Source Data Processing.American journal of clinical pathology · 2022Article
- Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Review
- Amyloidosis: What does pathology offer? The evolving field of tissue biopsy.Frontiers in cardiovascular medicine · 2022Review
- An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma.Clinical case reports · 2021Article
- Anaesthetic challenges in the spine surgery of a young Asian man with lumbar amyloidosis.BMJ case reports · 2021Article
- Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.